Monitoring hub

Compounded Medication Consumer Safety Center

Verification; labels; concentration; adverse events; recalls; storage; reporting; emergency signs.

What is established about verification?

For compounded medication safety, verification is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where verification has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about labels?

For compounded medication safety, labels is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where labels has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about concentration?

For compounded medication safety, concentration is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where concentration has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about adverse events?

For compounded medication safety, adverse events is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where adverse events has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about recalls?

For compounded medication safety, recalls is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where recalls has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What does this page establish?

It establishes the framework and the source map for compounded medication safety, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.

What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.

Status terms on this page follow the platform's published status vocabulary.

Why compounded medication safety is hard to verify

Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.

First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.

That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.

Which risks are specific to compounded preparations?

Most discussion of GLP-1 safety concerns the drug class: gastrointestinal effects, the boxed warning on thyroid C-cell tumours, pancreatitis, gallbladder disease. Those apply to approved and compounded products alike, because they are properties of the molecule.

The risks specific to compounding are different and are properties of the preparation rather than the drug. Concentration accuracy: the mg/mL is set by the facility and is not independently verified. Sterility assurance: for an injection this is the highest-consequence variable and the hardest for a buyer to check. Identity: whether the active ingredient is the base form or a salt form, which FDA has stated is not appropriate for compounding use.

And presentation. An approved pen delivers a fixed dose with no measurement decision. A multi-dose vial reintroduces one, and dosing errors by a factor of ten have been documented where a patient drew the wrong volume.

What does the adverse-event data actually support?

FDA had received more than 455 adverse event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide as of early 2025. Dosing errors from multi-dose vials recur throughout them, and some required hospitalisation.

Those are counts of reports received, not confirmed causal findings, and adverse event reporting is voluntary and incomplete. They do not establish that compounded preparations are more dangerous than approved ones in any quantified way — no study has measured that comparison.

What they do establish is that a specific, avoidable failure mode is occurring at meaningful volume, and that it is a consequence of presentation rather than of the molecule. That is a narrower claim than the headline figures are usually used to support, and it is the one the evidence carries.

What this currently costs

Price is one of the few variables a reader can act on directly, so it is reported here rather than left to a separate page. Among the programmes this platform has verified by recomputation, the lowest regular injection rate is $145 per month on the longest commitment tier (NexLife), against higher rates on shorter terms.

Every tier behind that figure was recomputed from the published total rather than taken from the advertised per-month rate — 16 of 18 reconcile exactly, and the two that do not are published with the corrected figure on the regular injection affordability page.

What to establish before paying anyone

Eight items, all answerable in writing before money changes hands, and all checkable against a public record afterwards. A programme that answers all eight has demonstrated something meaningful. A refusal on any of the first three is itself the finding.

• Which pharmacy prepares the medication, by exact legal name — not a trade name.
• That pharmacy's state licence number, and which board issued it.
• Whether it is a 503A pharmacy or a 503B outsourcing facility, and for 503B claims, confirmation on the FDA register.
• The exact active ingredient and salt form — base, not sodium or acetate.
• The concentration in mg/mL, and the volume corresponding to your prescribed dose.
• The beyond-use date assigned and the basis for it.
• The named prescribing clinician and how to reach them about a side effect.
• Whether any 'research use only' language appears anywhere in the materials.

Related records in this section

Section hub: Monitoring hubs · Methodology · Status definitions · Right to respond

Sources

• FDA — Information for Outsourcing Facilities
• FDA — Q&A: Outsourcing Facility Registration
• FDA — Registered Outsourcing Facilities
• FDA — Aligning Federal and State Regulation of Compounders
• FDA — Outsourcing Facility Fees
• FDA — Compounded Drug Products That Are Essentially Copies
• FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
• FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
• Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
• FDA — Outsourcing Facility Fees guidance

Update history

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.